Infammasomes provide a therapeutic target against human diseases

The structure of inflammasomes and their role in diseases.

J&J targets generalised myasthenia gravis landscape with nipocalimab – Pharmaceutical Technology

Nipocalimab is an IgG receptor FcRn large subunit p51 antagonist designed to compete with IgG in binding to FcRn. Credits: Skorzewiak/Shutterstock.com Johnson & Johnson (J&J)

August 30, 2024

Neurofilament Light Predicts MS Worsening in Silent Progression

Neuroaxonal pathology occurred in advance of — not coincident with — clinical worsening in multiple sclerosis (MS), particularly in patients with “silent progression” or progression

October 18, 2023

A single drug and multiple study failures leave Anavex with nothing but cash

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome. The negative study outcome was

January 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.